Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Amneal Pharmaceuticals (NYSE:AMRX) and raised the price target from $4 to $5.
August 07, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on Amneal Pharmaceuticals and raised the price target from $4 to $5, which could lead to a positive market reaction.
The raised price target by Barclays indicates a positive outlook for Amneal Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100